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Brief report
Asparagine synthetase expression is linked with L-asparaginase resistance in
TEL-AML1–negative but not TEL-AML1–positive pediatric
acute lymphoblastic leukemia
Wendy A. G. Stams, Monique L. den Boer, Amy Holleman, Inge M. Appel, H. Berna Beverloo, Elisabeth R. van Wering,
Gritta E. Janka-Schaub, William E. Evans, and Rob Pieters
Resistance to L-asparaginase in leuke-
mic cells may be caused by an elevated
cellular expression of asparagine syn-
thetase (AS). Previously, we reported
that high AS expression did not corre-
late to L-asparaginase resistance in TEL-
AML1–positive B-lineage acute lympho-
blastic leukemia (ALL). In the present
study we confirmed this finding in TEL-
AML1–positive patients (n  28) using
microarrays. In contrast, 35 L-asparagi-
nase–resistant TEL-AML1–negative B-
lineage ALL patients had a significant
3.5-fold higher AS expression than 43
sensitive patients (P < .001). Using real-
time quantitative polymerase chain reac-
tion (RTQ-PCR), this finding was con-
firmed in an independent group of 39
TEL-AML1–negative B-lineage ALL pa-
tients (P  .03). High expression of AS
was associated with poor prognosis
(4-year probability of disease-free sur-
vival [pDFS] 58%  11%) compared with
low expression (4-year pDFS 83%  7%;
P  .009). We conclude that resistance
to L-asparaginase and relapse risk are
associated with high expression of AS
in TEL-AML1–negative but not TEL-
AML1–positive B-lineage ALL. (Blood.
2005;105:4223-4225)
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Introduction
L-asparaginase (L-Asp) is an enzyme widely used in chemothera-
peutic protocols for treatment of children with acute lymphoblas-
tic leukemia (ALL). In vitro and in vivo resistance to L-Asp
correlates with a relatively poor prognosis in ALL.1,2 L-Asp
depletes asparagine and glutamine in blood cells.3 Impaired
capacity to synthesize sufficient amounts of asparagine due to
reduced asparagine synthetase (AS) levels is thought to explain
the L-Asp sensitivity of ALL cells to L-Asp treatment.4,5 L-Asp
resistance is suggested to be caused by an elevated cellular level
of AS.6
TEL-AML1–positive ALL patients are more sensitive to
L-Asp compared with TEL-AML1–negative patients.7,8 How-
ever, we found a 5-fold higher expression of AS in the
TEL-AML1–positive ALL patients compared with TEL-AML1–
negative ALL patients,7 recently confirmed by Krejci et al.9
Therefore, within TEL-AML1–positive ALL, resistance to L-Asp
is not associated with AS expression levels. Due to limited
sample size in our previous study, it was unclear if this
conclusion could be generalized for all other B-lineage ALL
patients. Therefore, we investigated the relationship between AS
expression and L-Asp resistance in 2 independent and larger
groups of TEL-AML1–negative ALL patients.
Study design
Patient samples
Bone marrow and/or peripheral blood samples from 117 untreated children
with TEL-AML1–negative and 28 untreated children with TEL-AML1–
positive B-lineage ALL at initial diagnosis were collected at the Erasmus
MC–Sophia Children’s Hospital, by the Dutch Childhood Oncology Group,
and by the German Cooperative Acute Lymphoblastic Leukemia (COALL)
Study Group. Samples were collected after informed consent was obtained
from patients or their parents or guardians, according to the Declaration of
Helsinki. The informed consent was approved by the Medical Ethics
Committee, Erasmus MC. In addition, samples from 17 TEL-AML1–
negative ALL patients used in our previous study were included.7 Within 24
hours after sampling, mononuclear cells were isolated and total cellular
RNA was extracted from a minimum of 5 106 leukemic cells ( 90%
leukemic cells) using Trizol reagent (Life Technologies, Gaithersburg,
MD), as described before.7
Microarray analysis
RNA processing and hybridization to the U133A GeneChip oligonucleotide
microarray (Affymetrix, Santa Clara, CA) was performed according to
manufacturer’s protocol. Data analysis was performed as described be-
fore.10 For this study, we limited the analysis to AS data in in vitro
L-Asp–sensitive and –resistant TEL-AML1–positive (23 and 5 patients,
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respectively) and TEL-AML1–negative patients (43 and 35 patients,
respectively).
Real-time quantitative polymerase chain reaction (RTQ-PCR)
The mRNA expression level of AS and an endogenous housekeeping gene
encoding for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a
reference were quantified using real-time PCR analysis (Taqman
chemistry) with efficiencies of at least 95%, as described before.7 The
relative expression level of AS to GAPDH is calculated using the
comparative cycle time method.7
In vitro L-Asp cytotoxicity assay
In vitro L-Asp (Paronal, Christiaens B.V., Breda, The Netherlands) cytotox-
icity was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay as described previously.7 Cutoff
criteria for sensitive (LC50  0.033 IU/mL), intermediate sensitive, and
resistant (LC50  0.912 IU/mL) toward L-Asp were as previously de-
scribed.11 These 3 groups were associated with prognosis of ALL patients.11
Statistics
Differences in mRNA expression between groups of patients were analyzed
using the Mann-Whitney U test. The correlation between AS expression and
L-Asp resistance was calculated using the Spearman rank correlation test.
Probability of disease-free survival (pDFS) was calculated from the date of
diagnosis to the date of nonresponse, relapse, or last contact using the
Kaplan-Meier method and compared by log-rank test. Multivariate analysis
was performed with the Cox proportional hazard regression model.
Results and discussion
AS expression was analyzed with microarray technology in 78
TEL-AML1–negative and 28 TEL-AML1–positive ALL patients.
No difference in AS expression between L-Asp–resistant (n 5;
median, 828 arbitrary units [AUs]; P25-P75: 164-1871) and
L-Asp–sensitive (n 23; median, 516 AUs; P25-P75: 141-689;
P  0.3) patients was found within TEL-AML1–positive ALL
patients, which is in concordance with earlier findings from our lab
and others.7,9 However, in TEL-AML1–negative ALL patients a
significant 3.5-fold difference in AS expression was shown between
L-Asp–resistant (n 35; median, 946 AUs; P25-P75: 293-1617)
and –sensitive (n 43; median, 244 AUs; P25-P75: 92-787)
patients (P  .001; Figure 1).
The original TEL-AML1–negative ALL patient group (n 17)
from our previous study7 was enlarged to a total of 39 patients
(different patients than used for microarray analysis) and AS
expression was analyzed by RTQ-PCR. A significant positive
correlation was found between AS expression and L-Asp resistance
(Rs  0.39; P  .017). Patients were divided in 3 subgroups based
on in vitro cellular toxicity to L-Asp (ie, 10 sensitive, 15 intermedi-
ate sensitive, and 14 resistant patients to L-Asp). A significant
3.5-fold higher AS expression was shown in L-Asp–resistant
compared with L-Asp–sensitive TEL-AML1–negative ALL patients
(P  .03; Figure 2), which is in concordance with our microarray
data (Figure 1).
The mRNA expression level of AS does not necessarily
correlate with protein level and enzyme activity of AS. However,
Hutson et al12 showed in human leukemia cell lines that complete
amino acid deprivation resulted in a simultaneous increase in AS
mRNA, protein, and enzymatic activity, suggesting that mRNA
corresponds to protein and activity levels.
Based largely on in vitro observations in (non) human leukemia
cell lines, it has been hypothesized that elevated AS activity is a
cause of L-Asp resistance in human leukemia cells lines.6,12-17 Only
a few studies have reported this relation between AS expression and
L-Asp sensitivity in patient materials.18,19 We and others showed
previously that AS expression is not related to L-Asp sensitivity in
TEL-AML1–positive ALL.7,9 We now confirmed this with a second
method (ie, microarray analysis). In contrast, we show in 2
independent groups of patients studied by 2 different techniques
(microarray and RTQ-PCR) that elevated AS expression is
related to L-Asp resistance in TEL-AML1–negative ALL pa-
tients. This is in line with the in vitro observations in human and
nonhuman leukemia cell lines.6,12-17
The 78 TEL-AML1–negative patients analyzed by microarray
had a median follow-up of 4.4 years (range, 0.6-9.1 years) for
patients at risk. The clinical characteristics of L-Asp–resistant and
–sensitive patients were respectively as follows: white blood cell
(WBC) count of median 25.6 109/L (P25-P75: 7.7-52.0) and
26.8 109/L (P25-P75: 8.8-73.2) (P  .8); age of median 8.0
(P25-P75: 4.5-11.5) and 4.0 years (P25-P75: 2.0-7.3) (P  .001).
High AS expression (above median value) was associated with a
poor prognosis (4-year pDFS 58% 11%) compared with low AS
expression (4-year pDFS 83% 7%; P  .009). Furthermore, the
AS expression in patients who relapsed (946 AUs, P25-P75:
305-2153) was 2.5-fold higher compared with patients who had not
yet relapsed (379 AUs, P25-P75: 101-932; P  .01). Multivariate
analysis including WBC count and age revealed that high AS
Figure 1. AS expression in TEL-AML1–negative ALL determined by microarray.
AS expression in TEL-AML1–negative ALL patients sensitive (n  43) and resistant
to L-Asp (n  35; P  .001) as determined by microarray analysis. E represents
individual patients; bars represent the median values. AU indicates arbitrary units
defined as scaled fluorescence measured on microarray.
Figure 2. AS expression in TEL-AML1–negative ALL determined by RTQ-PCR.
AS expression in TEL-AML1–negative ALL patients sensitive (n  10) and
resistant to L-Asp (n  14; P  .03) as determined by RTQ-PCR. AS mRNA
expression is indicated in arbitrary units (AUs) and defined as the mRNA
expression of AS relative to GAPDH  100. E represents individual patients;
bars represent the median values.
4224 STAMS et al BLOOD, 1 JUNE 2005  VOLUME 105, NUMBER 11
expression is independently related to a poor prognosis (hazard
ratio, 3.0; 95% confidence interval [CI], 1.1-7.9; P  .03). In
contrast, we recently showed that the expression of AS in
TEL-AML1–positive ALL is not related to outcome.20 Krejci et
al9 even found the opposite: a relation between high AS
expression and a good prognosis in TEL-AML1–positive ALL
patients. These data suggest that the role of AS for L-Asp
resistance and therapy is different between both genetic sub-
types. Since the TEL-AML1 genotype is associated with an
increased L-Asp sensitivity,7,8 the mechanism of action (and
hence cause of resistance) may be different. A possibility might
be the higher expression levels of the proapoptotic protein CD95
in TEL-AML1–positive ALL cells compared with TEL-AML1–
negative ALL cells,21 since the CD95-mediated pathway is
activated by cell shrinkage, which can be mediated by L-Asp.22
An alternative explanation might be that TEL-AML1–positive
ALL cells are not able to provide sufficient amounts of the AS
substrates aspartate and glutamine, due to different amino acid
metabolism and/or transmembrane amino acid transporters that
contribute to the function of AS.23 Further detailed studies are
required to understand the observed difference between TEL-
AML1–negative and –positive subtypes.
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